Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR3 | P49019 | 3/20 | 0.60 |
| ▸ | WNK1 | Q9H4A3 | 2/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 6/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 5/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21294007 | 1.00 | HCAR3 (0.60) | HCAR3WNK1MAPK1KMT2AMEN1 | |
| SCHEMBL29741389 | 1.00 | HCAR3 (0.60) | HCAR3WNK1MAPK1KMT2AMEN1 | |
| SCHEMBL20096272 | 1.00 | HCAR3 (0.60) | HCAR3WNK1MAPK1KMT2AMEN1 | |
| SCHEMBL17678246 | 0.93 | HCAR3 (0.64) | HCAR3WNK1MAPK1KMT2AMEN1 | |
| SCHEMBL14247576 | 0.89 | MAPT (0.53) | HCAR3WNK1MAPK1KMT2AMEN1 | |
| SCHEMBL14247574 | 0.89 | MAPT (0.53) | HCAR3WNK1MAPK1KMT2AMEN1 | |
| SCHEMBL24913721 | 0.87 | HCAR3 (0.51) | HCAR3WNK1MAPK1KMT2AMEN1 | |
| SCHEMBL28546794 | 0.87 | HCAR3 (0.51) | HCAR3WNK1MAPK1KMT2AMEN1 | |
| SCHEMBL30980938 | 0.87 | HCAR3 (0.51) | HCAR3WNK1MAPK1KMT2AMEN1 | |
| SCHEMBL17678250 | 0.87 | HCAR3 (0.66) | HCAR3WNK1MAPK1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12497392-B2 | EP300/CBP inhibitor | HINOVA PHARMACEUTICALS INC. (CN) | 2025-12-16 | — | — | US | disclosed |
| CN-112574189-B | EP300/CBP inhibitor | 海创药业股份有限公司 | 2024-05-31 | — | — | CN | disclosed |
| US-20230027088-A1 | EP300/CBP INHIBITOR | HINOVA PHARMACEUTICALS INC. (CN) | 2023-01-26 | — | — | US | disclosed |
| CN-110036002-B | Pharmaceutical compounds | 细胞中心有限公司 | 2022-08-30 | — | — | CN | disclosed |
| EP-4043458-A1 | EP300/CBP INHIBITOR | Hinova Pharmaceuticals Inc. (CN) | 2022-08-17 | — | — | EP | disclosed |
| US-11377443-B2 | Pharmaceutical compounds | CellCentric Limited (GB) | 2022-07-05 | — | — | US | disclosed |
| CN-110049983-B | Pharmaceutical compounds | 细胞中心有限公司 | 2022-06-14 | — | — | CN | disclosed |
| WO-2021057915-A1 | EP300/CBP INHIBITOR | 成都海创药业有限公司 | 2021-04-01 | — | — | WO | disclosed |
| CN-112574189-A | EP300/CBP inhibitor | 海创药业股份有限公司 | 2021-03-30 | — | — | CN | disclosed |
| US-20200407349-A1 | PHARMACEUTICAL COMPOUNDS | CellCentric Limited (GB) | 2020-12-31 | — | — | US | disclosed |
| EP-3529248-B1 | PHARMACEUTICAL COMPOUNDS | CELLCENTRIC LTD (GB) | 2020-08-19 | — | — | EP | disclosed |
| EP-3529240-B1 | PHARMACEUTICAL COMPOUNDS | CELLCENTRIC LTD (GB) | 2020-08-05 | — | — | EP | disclosed |
| US-10696666-B2 | Pharmaceutical compounds | CellCentric Limited (GB) | 2020-06-30 | — | — | US | disclosed |
| US-10647704-B2 | Pharmaceutical compounds | CELLCENTRIC LTD (GB) | 2020-05-12 | — | — | US | disclosed |
| US-20190263788-A1 | PHARMACEUTICAL COMPOUNDS | CELLCENTRIC LTD (GB) | 2019-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12497392-B2 | EP300/CBP inhibitor | EP300, MLLT1, CREBBP | HCAR3 2697/4885WNK1 2886/4885MAPK1 435/4885 |
| US-20200407349-A1 | PHARMACEUTICAL COMPOUNDS | EP300, HDAC1, HDAC11 | HCAR3 2357/4885WNK1 2134/4885MAPK1 480/4885 |
| US-20230027088-A1 | EP300/CBP INHIBITOR | EP300, MLLT1, CREBBP | HCAR3 2697/4885WNK1 2886/4885MAPK1 435/4885 |
| US-10647704-B2 | Pharmaceutical compounds | EP300, HDAC1, HDAC11 | HCAR3 3226/4885WNK1 2783/4885MAPK1 1035/4885 |
| US-11377443-B2 | Pharmaceutical compounds | EP300, HDAC1, HDAC11 | HCAR3 2357/4885WNK1 2134/4885MAPK1 480/4885 |
| US-20190263788-A1 | PHARMACEUTICAL COMPOUNDS | EP300, HDAC1, HDAC11 | HCAR3 3226/4885WNK1 2783/4885MAPK1 1035/4885 |
| US-10696666-B2 | Pharmaceutical compounds | EP300, HDAC1, HDAC11 | HCAR3 2357/4885WNK1 2134/4885MAPK1 480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.